TopoTarget's CEO Peter Buhl Jensen appointed Honorary Professor of Clinical Oncology at the University of Copenhagen

TopoTarget A/S
Symbion
Fruebjergvej 3
2100 København
Tlf.: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com



TopoTarget's CEO Peter Buhl Jensen appointed Honorary Professor of Clinical
Oncology at the University of Copenhagen 

Copenhagen, Denmark, 8 October 2007 - TopoTarget (OMX: TOPO) is pleased to
announce that MD Peter Buhl Jensen, CEO of TopoTarget, has been appointed
Honorary Professor of Clinical Oncology at the Institute of Surgery and
Internal Medicine, University of Copenhagen. 

“The university may award the title of Honorary Professor to individuals who
have excelled in their field of expertise and whom the university wishes to
honour and form a closer relationship with. Peter Buhl Jensen's appointment is
on the basis of his internationally peer-reviewed research projects that have
produced unique results which ultimately benefit cancer patients,” said Ulla
Wewer, Dean at the University of Copenhagen. 

Research conducted by Peter Buhl Jensen and his team at TopoTarget is founded
upon a research tradition established by the Finsen Institute and the
University Hospital in Copenhagen and it bridges the gap between laboratory
research and the treatment of cancer patients. Peter Buhl Jensen established
his research reputation as head of the Laboratory for Experimental Medical
Oncology at the National University Hospital and later as co-founder and CEO of
TopoTarget. 

“Since TopoTarget's foundation we have enjoyed a supportive and productive
relationship with the University Hospital in Copenhagen and the University of
Copenhagen. The University Hospital in Copenhagen has been visionary and the
support we received has meant that we were able to pursue our vision at
TopoTarget to become a European dynamo in the development of cancer
treatments,” said Peter Buhl Jensen. 


TopoTarget A/S

 

For further information, please contact:

Dr. Peter Buhl Jensen		Telephone	+45 39 17 83 41
Chief Executive Officer		Mobile	+45 21 60 89 22

Ulla Hald Buhl			Mobile	+45 21 70 10 49
Director of IR and Communications	


Background information

About TopoTarget
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with
subsidiaries in US, Switzerland, Germany and the UK, dedicated to finding
''Answers for cancer'' and developing improved cancer therapies. TopoTarget is
founded and run by clinical cancer specialists and combines years of hands-on
clinical experience with in-depth understanding of the molecular mechanisms of
cancer. Focus lies on highly predictive cancer models and key cancer targets
(including HDACi, NAD+, mTOR, FASligand and topoisomerase II inhibitors) and a
strong development foundation has been built. TopoTarget has a broad portfolio
of small molecule pre-clinical drug candidates and eight drugs (both small
molecules and protein based) are in clinical development, including both novel
anti-cancer therapeutics and new cancer indications for existing drugs.
Savene™/Totect™ was approved by EMEA in 2006 and the FDA in 2007 and is
TopoTarget's first product on the market. For more information, please refer to
www.topotarget.com. 

TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements.  TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks;  uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.